Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Strong Sell at Zacks Research

Zacks Research downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a strong sell rating in a report published on Monday,Zacks reports.

Several other research firms have also recently issued reports on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Finally, Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Up 0.5%

Shares of SUPN opened at $43.05 on Monday. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -22.42, a PEG ratio of 0.79 and a beta of 0.55. The firm’s fifty day simple moving average is $44.42 and its 200-day simple moving average is $46.79. Supernus Pharmaceuticals has a twelve month low of $40.51 and a twelve month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business’s revenue for the quarter was up 32.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.40 EPS. On average, analysts predict that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mystic Asset Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $1,181,000. Bank of America Corp DE increased its stake in shares of Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after acquiring an additional 193,479 shares during the period. BlackRock Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $434,871,000. Allworth Financial LP purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $2,357,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at about $1,298,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.